Q3 2021 Investor Relations Results

Participants Financial review Conclusion Appendix Company overview Pharmaceuticals Oncology Financial performance Innovation: Pipeline overview Novartis submission schedule New Molecular Entities: Lead and supplementary indications NEW INDICATIONS LEAD INDICATIONS 2021 177Lu-PSMA-617 AAA617 mCRPC 3L asciminib ABL001 CML 3L tislelizumab VDT482 2L esophageal cancer 2022 Lead ligelizumab QGE031 2023 Lead iptacopan Lead CSU Lead sabatolimab¹ Lead MBG453 Lead HR-MDS LNP023 PNH References Innovation: Clinical trials 2024 ≥2025 JDQ443 JDQ443 Lead 177 Lu-NeoB Lead ganaplacide Lead LXH254 Lead AAA603 KAF156 Solid tumors (combos) 2/3L NSCLC (mono) Multiple Solid Tumors Malaria uncomplicated remibrutinib Lead LOU064 branaplam LMI070 Lead iscalimab Lead MIJ821 Lead CFZ533 Depression CSU Huntington's disease Sjögren's syndrome UNR844 Lead Lead ianalumab Presbyopia YTB323 Lead 2L r/r Diffuse large B-cell lymphoma VAY736 Sjögren's syndrome CEE321 Atopic Dermatitis cipargamin KAE609 Malaria severe CPK850 RP Lead icenticaftor QBW251 COPD Lead libvatrep SAF312 COSP TQJ230 CVRR-Lp(a) Lead spartalizumab Lead NIS793 Lead 1L Pancreatic cancer Lead pelacarsen Lead Lead PDR001 Metastatic melanoma (combo) CSJ117 Asthma Lead LNA043 Lead TNO155 Lead Knee osteoarthritis Solid tumors gevokizumab VPM087 Lead LXE408 Visceral leishmaniasis 1st line CRC / 1st line RCC Lead tropifexor&licogliflozi Lead LJN452 NASH (combos) tislelizumab VDT482 1L Nasopharyngeal Carcinoma tislelizumab VDT482 NSCLC LCM 177Lu-PSMA-617 LCM AAA617 Pre-taxane LCM iptacopan LNP023 C3G tislelizumab LCM 177Lu-PSMA-617 LCM asciminib LCM iptacopan VDT482 1L ESCC LCM tislelizumab VDT482 AAA617 MHSPC ABL001 CML 1L LCM sabatolimab LCM asciminib MBG453 ABL001 Localized ESCC Unfit AML CML, 2L, pediatrics iptacopan LCM tislelizumab LCM tislelizumab LCM cipargamin LNP023 IgAN tislelizumab VDT482 VDT482 VDT482 KAE609 1L Hepatocellular Carcinoma 1L Small Cell Lung Cancer Malaria uncomplicated LCM 1L Gastric Cancer tislelizumab VDT482 1L Bladder Urothelial Cell Carcinoma LCM ianalumab VAY736 АІН LNP023 aHUS LCM iptacopan LNP023 iMN LCM iscalimab CFZ533 Liver Tx LCM ligelizumab QGE031 Food allergy LCM remibrutinib LOU064 LCM ligelizumab QGE031 CINDU LCM LCM Sjögren's syndrome LCM remibrutinib LCM LOU064 Multiple sclerosis LCM 1. Filing opportunity in 2022 / 2023, based on PFS and/or OS outcomes from a dual approach based on parallel Phase 2 and Phase 3 trials. 57 Investor Relations | Q3 2021 Results NOVARTIS | Reimagining Medicine

View entire presentation